Adaptive Biotechnologies Corp ADPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADPT is a good fit for your portfolio.
News
-
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
-
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
-
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
-
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
-
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
Trading Information
- Previous Close Price
- $2.92
- Day Range
- $2.64–2.82
- 52-Week Range
- $2.53–9.03
- Bid/Ask
- $2.79 / $2.80
- Market Cap
- $406.26 Mil
- Volume/Avg
- 753,738 / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.26
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 709
- Website
- https://www.adaptivebiotech.com
Comparables
Valuation
|
Metric
|
ADPT
|
ANAB
|
COGT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.25 | 6.69 | 3.04 |
Price/Sales | 2.26 | 34.78 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
ADPT
ANAB
COGT
Financial Strength
|
Metric
|
ADPT
|
ANAB
|
COGT
|
|---|---|---|---|
Quick Ratio | 4.37 | 10.62 | 6.96 |
Current Ratio | 4.66 | 10.87 | 7.09 |
Interest Coverage | −16.45 | −9.09 | — |
Quick Ratio
ADPT
ANAB
COGT
Profitability
|
Metric
|
ADPT
|
ANAB
|
COGT
|
|---|---|---|---|
Return on Assets (Normalized) | −18.06% | −23.50% | −49.77% |
Return on Equity (Normalized) | −35.04% | −75.96% | −75.04% |
Return on Invested Capital (Normalized) | −28.06% | −68.56% | −59.65% |
Return on Assets
ADPT
ANAB
COGT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zvsdckbj | Pzjp | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mdjrkrcv | Tssqxlq | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jsdpdbsfq | Bzfhgc | $98.6 Bil | |
MRNA
| Moderna Inc | Rrpqktty | Vtwd | $41.0 Bil | |
ARGX
| argenx SE ADR | Cylthgbf | Dkgd | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Xtkhrysd | Kvlv | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Tpxrnysp | Pbfbrv | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bjdjgmz | Pzyhjg | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zhfzqlgbsz | Zsjms | $12.6 Bil | |
INCY
| Incyte Corp | Pzynrtbl | Mgcbvt | $12.0 Bil |